Table 3 Results of the case/non-case analysis to identify an increased reporting risk of movement disorder for each of the 9 movement disorders for all antidepressants compared to all other drugs in VigiBase®

2160

1,025,245

1,027,405

3.79 [3.61–3.98]

<.0001

7359

13,235,682

13,243,041

9519

14,260,927

14,270,446

1244

1,026,161

1,027,405

10.37 [9.62–11.17]

<.0001

1548

13,241,493

13,243,041

2792

14,267,654

14,270,446

5113

1,022,292

1,027,405

2.07 [2.01–2.14]

<.0001

31,870

13,211,171

13,243,041

36,983

14,233,463

14,270,446

1944

1,025,461

1,027,405

4.79 [4.55–5.05]

<.0001

5237

13,237,804

13,243,041

7181

14,263,265

14,270,446

3695

1,023,710

1,027,405

2.14 [2.07–2.22]

<.0001

22,289

13,220,752

13,243,041

25,984

14,244,462

14,270,446

2430

1,024,975

1,027,405

5.14 [4.90–5.38]

<.0001

6111

13,236,930

13,243,041

8541

14,261,905

14,270,446

2598

1,024,807

1,027,405

1.55 [1.49–1.61]

<.0001

21,625

13,221,416

13,243,041

24,223

14,246,223

14,270,446

770

1,026,635

1,027,405

1.49 [1.38–1.60]

<.0001

6667

13,236,374

13,243,041

7437

14,263,009

14,270,446

28,021

999,384

1,027,405

3.06 [3.02–3.10]

<.0001

120,400

13,122,641

13,243,041

148,421

14,122,025

14,270,446